Lupaneta Pack

Endometriosis, Iron Deficiency Anemia, Iron replacement therapy + 6 more

Treatment

20 Active Studies for Lupaneta Pack

What is Lupaneta Pack

Leuprolide

The Generic name of this drug

Treatment Summary

Leuprolide is a synthetic hormone used to treat certain medical conditions. It is similar to a natural hormone called gonadotropin-releasing hormone (GnRH). Unlike GnRH, Leuprolide has a single D-amino acid (D-leucyl) residue which helps extend its lifespan in the body from a few minutes to up to three hours. Leuprolide triggers a decrease in sex steroid levels, which is why it is used to treat advanced prostate cancer, endometriosis, and central precocious puberty. It was first approved in 1985 and is available as a daily subcutaneous

Lupron

is the brand name

image of different drug pills on a surface

Lupaneta Pack Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Lupron

Leuprolide

1986

57

Effectiveness

How Lupaneta Pack Affects Patients

Leuprolide is a hormone that is used to treat endometriosis, uterine leiomyomata, advanced/metastatic prostate cancer, and central precocious puberty. It works by initially increasing hormone and steroid levels in the body, followed by a significant drop in levels. In women, it can worsen symptoms such as pain and bleeding, and long-term use can lead to bone-density loss. In men, it can cause tumour flare, bone pain, diabetes, and cardiovascular disease. In pediatric patients, it can cause convulsions and psychiatric symptoms. Careful consideration should be taken when using this

How Lupaneta Pack works in the body

Leuprolide is a drug that works on the hypothalamic-pituitary-gonadal (HPG) axis to treat various conditions. It binds to receptors in the brain and stimulates the release of hormones, like luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These hormones then affect the release of other sex hormones. After a few weeks, continuous stimulation of the receptors causes a decrease in LH, FSH, and other hormones, which produces a therapeutic benefit. When treatment ends, these effects go away.

When to interrupt dosage

The measure of Lupaneta Pack is contingent upon the acknowledged affliction, including Anger Management Therapy, Central Precocious Puberty (CPP) and Uterine Fibroids. The amount of dosage can be observed in the table below, subject to the technique of delivery (e.g. Intramuscular or Intramuscular; Topical).

Condition

Dosage

Administration

Endometriosis

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Palliative Treatment

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Puberty, Precocious

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Uterine Fibroids

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

symptom recurrence

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Prostatic Neoplasms

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

confirmed by clinical features

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Iron Deficiency Anemia

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Iron replacement therapy

, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg

, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Kit - Intramuscular; Topical, Intramuscular; Topical, Intramuscular; Oral; Topical, Kit - Subcutaneous; Topical, Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous

Warnings

Lupaneta Pack has six identified contraindications. Therefore, it should not be used when coping with any of the conditions shown in the following table.

Lupaneta Pack Contraindications

Condition

Risk Level

Notes

Vaginal Hemorrhage

Do Not Combine

Pregnant Women

Do Not Combine

Metrorrhagia

Do Not Combine

Breast Neoplasms

Do Not Combine

Liver Neoplasms

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Leuprolide may interact with Pulse Frequency

There are 20 known major drug interactions with Lupaneta Pack.

Common Lupaneta Pack Drug Interactions

Drug Name

Risk Level

Description

Amiodarone

Major

The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Amiodarone.

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Anagrelide.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Artemether.

Asenapine

Major

The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Asenapine.

Lupaneta Pack Toxicity & Overdose Risk

Leuprolide has been found to be a very safe drug, with little to no side effects related to dosage. Prostate cancer patients who were given a dose of leuprolide up to 20 mg/day for two years had no additional adverse effects compared to those taking 1 mg/day.

Lupaneta Pack Novel Uses: Which Conditions Have a Clinical Trial Featuring Lupaneta Pack?

144 active studies are currently being conducted to analyze the potential of Lupaneta Pack to reduce symptom recurrence, Uterine Fibroids and Iron Deficiency Anemia.

Condition

Clinical Trials

Trial Phases

Iron Deficiency Anemia

20 Actively Recruiting

Phase 3, Not Applicable, Phase 2, Phase 1, Phase 4

symptom recurrence

0 Actively Recruiting

Puberty, Precocious

1 Actively Recruiting

Phase 3

Endometriosis

27 Actively Recruiting

Early Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4

Prostatic Neoplasms

0 Actively Recruiting

confirmed by clinical features

0 Actively Recruiting

Palliative Treatment

1 Actively Recruiting

Phase 3

Iron replacement therapy

0 Actively Recruiting

Uterine Fibroids

13 Actively Recruiting

Phase 2, Early Phase 1, Phase 3, Not Applicable, Phase 4

Lupaneta Pack Reviews: What are patients saying about Lupaneta Pack?

3.3

Patient Review

2/3/2016

Lupaneta Pack for Endometriosis

A new medication to treat endometriosis.

Patient Q&A Section about lupaneta pack

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Lupron Depot kit?

"The drug LUPRON DEPOT 3.75 mg is used to treat endometriosis by reducing the amount of pain associated with the condition and shrinking the size of the endometriotic lesions."

Answered by AI

What is Lupron tablet used for?

"The generic name for leuprolide is leuprolide. It is used to treat advanced prostate cancer in men by reducing the amount of testosterone in the body. It is not a cure."

Answered by AI

What is Lupaneta pack used for?

"It is indicated for the initial management of the painful symptoms of endometriosis and for management of recurrence of symptoms."

Answered by AI

What is Lupron 11.25 used for?

"The LUPRON DEPOT–3 Month 11.25 mg is indicated for treating endometriosis, including reducing pain and reducing endometriotic lesions. LUPRON DEPOT with norethindrone acetate 5 mg daily is also indicated for treating endometriosis and for treating recurrence of symptoms."

Answered by AI

Clinical Trials for Lupaneta Pack

Image of University Hospitals Cleveland Medical Center in Cleveland, United States.

Ketamine for Pelvic Pain

18 - 89
Female
Cleveland, OH

The purpose of this research study is to see if ketamine infusion during surgery can decrease pain after surgery. Ketamine is a medication commonly used as part of anesthesia during surgery and is approved by the US FDA. Patients will be randomized to either receive standard anesthesia with OR without ketamine. The surgical procedure will be the same regardless of which group patients are randomized to. After surgery, patients will be asked to rate their pain in the post-operative observation unit and at their two-week post-operative visit. No additional visits are required for participation in this study. The investigators estimate the surveys will take approximately 10 minutes to complete.

Phase 4
Waitlist Available

University Hospitals Cleveland Medical Center

Morgan Cheeks, MD

Have you considered Lupaneta Pack clinical trials?

We made a collection of clinical trials featuring Lupaneta Pack, we think they might fit your search criteria.
Go to Trials
Image of Hospital of the University of Pennsylvania in Philadelphia, United States.

Educational Video for Uterine Fibroids

18 - 55
All Sexes
Philadelphia, PA

Uterine fibroids are a common condition that can cause heavy and/or painful menstrual bleeding. There are many treatment options, but they vary in efficacy, side effects, short-term recovery and long-term implications for future fertility. Patients can have difficulty deciding between these options. In this study, the investigators will randomly assign patients seeking treatment for fibroids to receive an educational video on fibroids and their treatment, versus usual care (no video). The investigators will assess their decisional conflict with and without exposure to the video using a validated survey to see if exposure to the educational video helps them make decisions.

Recruiting
Has No Placebo

Hospital of the University of Pennsylvania

Anuja Dokras, MD

Image of University Health Network (UHN) in Toronto, Canada.

Mitapivat for Anemia

18+
All Sexes
Toronto, Canada

This is a prospective exploratory phase 2 study designed to evaluate the safety and efficacy of mitapivat in RBC membranopathies and CDAII, a rare sub type of anemia. Nine patients from Princess Margaret who are diagnosed with CDAII will be enrolled to the study. Patients will be in the trial for 57 weeks treatment weeks and a safety follow up week after 30 days from last dose. First 8 weeks will be dose escalating period followed by 48 weeks of fixed dose period. 57th week will be dose tapering week. Data collected from Princes Margaret will be incorporated to the main study conducted in EU for analysis. Overall, approximately 25 patients are expected to be enrolled: Approximately 16 patients at sites in the EU and approximately 9 patients in Canada.

Phase 2
Recruiting

University Health Network (UHN)

Agios Pharmaceuticals, Inc.

Have you considered Lupaneta Pack clinical trials?

We made a collection of clinical trials featuring Lupaneta Pack, we think they might fit your search criteria.
Go to Trials
Image of Alethios, Inc. in San Francisco, United States.

NettleEndo for Endometriosis

22 - 45
Female
San Francisco, CA

The goal of this clinical trial is to learn if a wearable brain stimulation device called NettleEndo can reduce chronic pelvic pain and improve wellbeing in women with endometriosis. The study also aims to assess the safety and usability of the device when used at home over several months. The main questions it aims to answer are: 1. Does at-home transcranial direct current stimulation (tDCS) reduce daily pain intensity in women with endometriosis? 2. Does the device also improve mood and sleep quality? Researchers will compare two groups-one receiving active brain stimulation and one receiving a sham (placebo) stimulation-to see if the active device provides greater improvements in symptoms. Participants will: 1. Use the NettleEndo device at home for 20 minutes per session, five times per week for 12 weeks 2. Be randomly assigned to receive either real or sham stimulation through the device 3. Complete daily and weekly symptom ratings through a mobile app 4. Be followed for 90 days after completing the intervention to monitor longer-term effects All activities are completed remotely using a smartphone app. Participants can contact the study team with questions at any time. The study is double-blind, meaning neither participants nor the researchers assessing outcomes will know who received active or sham treatment until the end of the trial.

Recruiting
Online Trial

Alethios, Inc.

Nirav Shah, MD, MPH

Samphire Group, Inc.

Image of Baylor College of Medicine in Hosuton, United States.

Dronabinol for Endometriosis

18 - 64
Female
Hosuton, TX

This exploratory, proof-of-concept study is a double-blind (participants and investigators will be blinded), placebo-controlled, randomized, two-arm clinical trial of Marinol \[dronabinol, synthetic Δ9-tetrahydrocannabinol (THC)\] for e endometriosis-associated chronic pelvic pain (endo-CPP) with a 2:1 allocation ratio. Up to 75 subjects will be enrolled in this pilot study and randomized to receive doses of THC (up to 30 mg/day), orally, over 8 weeks. This study will be conducted at a single site; it does not include any stratifications, and there is no interim analysis planned. Notably, the goal is to determine whether there is enough evidence of the safety of THC to support the development of later-phase clinical trials. Thus, detailed developmental plans are contingent on the outcomes of this study.

Phase 2
Waitlist Available

Baylor College of Medicine (+1 Sites)

Christopher Verrico, PhD in Pharmacology

Image of Weill Cornell Medical College in New York, United States.

Luspatercept for Clonal Cytopenia

18+
All Sexes
New York, NY

The purpose of this clinical trial is to test how well the drug luspatercept works in improving low blood cell counts in people with clonal cytopenias of uncertain significance (CCUS). The main questions the study seeks to answer include: * How many patients experience improvements in their low blood counts (red cells, platelets, or white cells) within 24 weeks, based on specific criteria for blood conditions like myelodysplastic syndromes (MDS)? * How long these improvements last before the condition worsens or changes. * The percentage of participants showing improvements at 12, 24, and 48 weeks. * How long it takes for the condition to progress to more severe diseases like myeloid disorders. * How long red blood cell responses last and how quickly these responses are seen. * The average change in hemoglobin levels over 24 weeks. * How many patients need blood transfusions during the study and how soon transfusions are required. * Changes in participants' well-being and energy levels based on a standardized questionnaire. * Monitoring for any side effects, including progression to MDS or leukemia, heart-related issues, or sudden increases in hemoglobin. Participants will: * Receive luspatercept as an injection every three weeks. * Visit the clinic every three weeks for treatment and monitoring.

Phase 2
Recruiting

Weill Cornell Medical College

Pinkal Desai, MD

Bristol-Myers Squibb

Have you considered Lupaneta Pack clinical trials?

We made a collection of clinical trials featuring Lupaneta Pack, we think they might fit your search criteria.
Go to Trials